SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff across AI neocloud stocks, fueled by concerns about financing costs and whether the sectors business models can deliver returns, has put NBIS in focus. Traders are split between viewing the drop as an overdone, oversold pullbackwith some citing NBISs stronger financial positionand expecting more downside amid lingering sector risks.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy has fueled a rebound discussion after a sharp selloff, with some traders seeing the decline as overdone and others warning that CoreWeaves heavy debt and financing needs remain a risk. The debate centers on whether AI demand and contracted business can outweigh concerns about borrowing costs and the companys ability to fund its expansion.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is drawing attention after stronger-than-expected third-quarter results and a sharply higher 2027 adjusted EBITDA outlook. Bulls are highlighting the improved outlook and potential short-covering, while skeptics question whether operating gains can ease the companys substantial debt burden.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for the 80th death event in SELLASs blinded Phase 3 REGAL trialand the final analysis of its GPS treatment for AMLis driving attention amid share-price weakness. Bulls interpret the delay and upcoming ASH meeting as possible signs of extended survival or data disclosure, while skeptics say the timeline and CEOs comments prove nothing; no outcome has been confirmed, and traders also watch for SLS009 data.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is drawing attention around AXPAXLIs prospects in wet AMD after competitor EyePoints trial setback. Some traders see fewer competitive threats and emphasize AXPAXLIs potential durability, while others argue the setback could fuel broader skepticism about TKI treatments; debate also centers on the companys pending NDA submission.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Traders are focused on XEs sharp post-IPO selloff, often blaming lockup-related share supply and weakness across nuclear and AI-linked stocks; concerns about the long path to commercialization and permitting also weigh on sentiment. Some holders remain bullish on Amazons backing and future data-center power demand, while others warn the selling may continue.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDAs clearance to expand Alpha Taus U.S. REGAIN recurrent-glioblastoma trial from 10 to 20 patients is drawing attention, alongside expectations for additional clinical data at the SNO meeting. Traders are broadly optimistic about the growing catalyst pipeline, while the early GBM results come from a very small cohort; completion of enrollment in the pancreatic IMPACT study is also contributing to the discussion.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results are drawing attention after wider mortgage spreads drove a sharp decline in book value and a reported loss, while earnings fell short of covering the monthly dividend. Traders are debating dividend sustainability and added risk from higher leverage, though some view the losses as largely unrealized and continue to favor the income stream.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

A broad biotech selloff, attributed by traders to rising-rate concerns, risk-off positioning and rotation away from smaller biotech stocks, is weighing on XBI. The community is split between expecting further weakness and viewing the sharp pullback as an oversold buying opportunity, with potential M&A and upcoming clinical catalysts cited as reasons for optimism.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp, high-volume rebound after a steep AI-infrastructure selloff has drawn attention to WULF, with traders highlighting CEO Paul Pragers CNBC defense of its power-and-data-center leasing model, which avoids owning rapidly depreciating chips, and bullish Morgan Stanley commentary. The community is split between viewing the move as a possible reversal and worrying that financing costs, leverage, and broader sector weakness could bring renewed selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Companys Board of Directors...

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Companys Board of...

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming...

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm PR Newswire NEW YORK, Aug. 19, 2026 NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +26.53% and +186.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the second quarter ended June 30...

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Arcus Biosciences Inc

Why Did Arcus Biosciences Stock Slump 10% Today?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The Phase 3 STAR-221 trial compared an anti-TIGIT and anti-PD-1 antibody duo plus chemotherapy to the established nivolumab-based regimen.</li><li>Arcus Biosciences is now concentrating its development resources on its HIF-2a inhibitor, casdatifan.</li><li>The company plans to call for multiple casdatifan data readouts and study initiations throughout 2026.</li></ul>Arcus Biosciences, Inc. (RCUS), announced on Friday that it is stopping its Phase 3 STAR-221 trial after it failed to show meaningful progress.The company will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival.<h2 class="st-heading-2">STAR-221 Study Discontinued</h2>The Phase 3 STAR-221 trial, which compared an anti-TIGIT and anti-PD-1 antibody duo plus chemotherapy to the established nivolumab-based regimen, did not show a survival advantage at the planned interim review.The decision marks a setback for the domvanalimab program, which was being developed alongside zimberelimab for advanced gastric and esophageal cancers.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/RCUS">Arcus Biosciences’ stock</a> traded 10% lower by mid-morning on Friday. On Stocktwits, retail sentiment around the stock changed to ‘extremely bearish’ from ‘bearish’ territory the previous day. Message volume changed to ‘high’ from ‘normal’ levels in the last 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:930/106;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_12_112646_png_edcaeadd11.webp" alt="RCUS’s Sentiment Meter and Message Volume as of 11:15 a.m. ET on Dec. 12, 2025 | Source: Stocktwits" width="930" height="106"><figcaption>RCUS’s Sentiment Meter and Message Volume as of 11:15 a.m. ET on Dec. 12, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Refocusing On Casdatifan</h2>With the STAR-221 trial ending, Arcus is concentrating its development resources on its HIF-2a inhibitor, casdatifan, which has shown encouraging single-agent results in clear cell renal cell carcinoma (ccRCC) studies.&nbsp;Early data demonstrated meaningful improvements in key measures such as response rates and progression-free survival in over 120 patients, and plans call for multiple casdatifan data readouts and study initiations throughout 2026.&nbsp;<blockquote>“The results from STAR-221 are not what we had hoped for, and we have important work ahead to meet the needs of patients on our domvanalimab studies and also accelerate the casdatifan and I&amp;I programs.”-Terry Rosen, CEO, Arcus</blockquote>RCUS stock has gained over 51% in 2025 and over 31% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fuzzy-panda-shorts-new-era-energy-and-digital-stock-we-believe-it-is-gray-s-next-flameout/cLICVVRREFy">Fuzzy Panda Shorts New Era Energy &amp; Digital Stock: ‘We Believe It Is Gray’s Next Flameout’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao.

Arcus will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$22.12
Prev Close	$22.82
Open	$22.79
Dividend Yield	0.00%
50-Day Moving Average	$26.94
Beta	1.58
Avg. Volume	1.74M
PE Ratio	-5.67

52-Week High	$31.74
52-Week Low	$16.35
Market Capitalization	$2.82B
EPS (Annual)	-$3.29
Price to Book	6.05
Revenue Per Employee	$410,981.70

Feed

News

Sentiment

Earnings

Fundamentals

Info

RCUS Fundamentals